soluble vcam 1 svcam 1 (R&D Systems)
R&D Systems is a verified supplier 
R&D Systems manufactures this product 
94
Structured Review
R&D Systems
soluble vcam 1 svcam 1
Soluble Vcam 1 Svcam 1, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 53 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/svcam+1/Human+VCAM-1%2FCD106+DuoSet+ELISA/pmc12790166-62-2-5
Average 94 stars, based on 53 article reviews
Soluble Vcam 1 Svcam 1, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 53 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/svcam+1/Human+VCAM-1%2FCD106+DuoSet+ELISA/pmc12790166-62-2-5
Average 94 stars, based on 53 article reviews
soluble vcam 1 svcam 1 - by Bioz Stars,
2026-10
94/100 stars
Images
1) Product Images from "Annual 12‐Week Dosing Gap of Natalizumab: Clinical Efficacy, Blood Biomarkers, and CSF Cell Composition"
Article Title: Annual 12‐Week Dosing Gap of Natalizumab: Clinical Efficacy, Blood Biomarkers, and CSF Cell Composition
Journal: Annals of Clinical and Translational Neurology
doi: 10.1002/acn3.70207
Figure Legend Snippet: Blood biomarker dynamics during the annual 12‐week dosing gap. (A) NfL serum levels measured during SID (baseline, time point A), at the end of the 12‐week dosing gap (time point B), as well as 3 months post gap (time point C). (B) SVCAM‐1 serum levels measured during SID (baseline, time point A), at the end of the 12‐week dosing gap (time point B), as well as 3 months post gap (time point C). (C) SVCAM‐1 levels correlated to NTZ serum levels measured at baseline (green, time point A) and at the end of the 12‐week dosing gap (orange, time point B). Spearman (non‐parametric) analysis revealed a significant correlation ( p value < 0.0001).
Techniques Used: Biomarker Discovery
Figure Legend Snippet: The annual 12‐week dosing gap modulates the composition of CSF immune cells. (A) Quantification of CD45+ CSF immune cell counts per ml by flow cytometry at time points A and B from six patients. (B) UMAP plots of CSF scRNAseq data immune cell subsets from nine patients at time points A (left) and B (right), annotated by aCSF. (C–I) Quantification of immune cell subset clusters as a percentage of cells within each sample from CSF of healthy donors (HD), treatment‐naïve MS (MS), and NTZ‐treated MS patients on SID (baseline, time point A) as well as after the A12WG (time point B). Only subsets with a significant increase from time points A and B are shown. (J–L) The scatterplots depict correlations between absolute changes from time points A and B of immune cell subset proportions in the CSF and serum concentrations of sVCAM‐1. Only significant positive correlations are shown. (M–N) The scatterplots depict correlations between absolute changes from time points A and B of immune cell subset proportions in the CSF and serum concentrations of NfL. Only significant correlations are shown. Statistical difference is indicated * p < 0.05. The circled dots indicate patients with MRI features after the treatment gap (patient #6, black; patient #8, blue).
Techniques Used: Flow Cytometry, Tandem Mass Spectroscopy
Figure Legend Snippet: Mechanism of action of natalizumab. (A) with a scenario where all VLA‐4‐expressing immune cells are blocked from trafficking into the CNS. Theoretical scenario (B) where some cells are blocked from trafficking into the CNS, while others are not. When VLA‐4 binds to VCAM‐1, sVCAM‐1 can be produced.
Techniques Used: Expressing, Produced
Related Articles
Clinical Proteomics:Article Title: Multi-study feasibility analysis on a composite biomarker of inflammatory resilience to quantify the effects of energy restriction on low-grade inflammation in overweight and obese individuals. Article Snippet: .. The following multiplexed immunoassays (provider, product number, units) were employed, and they were previously optimized for small plasma volumes using commercially available reference blood donor plasma samples (TCS Bioscience Ltd., Buckingham, UK) [10]: MPO (R&D Systems, DY3174), adiponectin (R&D Systems, DY1065), leptin (R&D Systems, DY398), E-selectin (R&D Systems, DY724), P-selectin (R&D Systems, DY137), sICAM-1 (R&D Systems, DY720), Article Title: Soluble Vascular Cell Adhesion Molecule-1 (VCAM-1) as a Biomarker in the Mouse Model of Experimental Autoimmune Myocarditis (EAM) Article Snippet: After digestion in 0.1% collagenase for 45 minutes, cells were lysed by ultrasonic pulse echo instrument. cVCAM-1, interleukin-6 (IL-6) and transforming growth factor-β (TGF-β) proteins were quantified using commercially available kits (VCAM-1: RayBiotech, Norcross, GA, Cat# ELM-VCAM1-001; IL-6: Cat#M6000B, TGF-β: Cat#MB100B, R&D Systems, Minneapolis, MN) according to the manufacturer’s instructions. .. For cVCAM-1, each value represents a pooled analysis of two hearts. Article Title: Multi-study feasibility analysis on a composite biomarker of inflammatory resilience to quantify the effects of energy restriction on low-grade inflammation in overweight and obese individuals Article Snippet: .. The following multiplexed immunoassays (provider, product number, units) were employed, and they were previously optimized for small plasma volumes using commercially available reference blood donor plasma samples (TCS Bioscience Ltd., Buckingham, UK) [ ]: MPO (R&D Systems, DY3174), adiponectin (R&D Systems, DY1065), leptin (R&D Systems, DY398), E-selectin (R&D Systems, DY724), P-selectin (R&D Systems, DY137), sICAM-1 (R&D Systems, DY720), Concentration Assay:Article Title: Gut Microbiota and Endothelial Dysfunction Markers in Obese Mexican Children and Adolescents Article Snippet: .. The concentration of EDF markers including Article Title: Gut Microbiota and Endothelial Dysfunction Markers in Obese Mexican Children and Adolescents. Article Snippet: .. The concentration of EDF markers including Blocking Assay:Article Title: Integrin cross-talk modulates stiffness-independent motility of CD4+ T lymphocytes Article Snippet: .. To activate or block integrins, cells were incubated with the following for 15 min prior to adhesion: Article Title: Integrin cross-talk modulates stiffness-independent motility of CD4+ T lymphocytes Article Snippet: .. To activate or block integrins, cells were incubated with the following for 15 min prior to adhesion: Incubation:Article Title: Integrin cross-talk modulates stiffness-independent motility of CD4+ T lymphocytes Article Snippet: .. To activate or block integrins, cells were incubated with the following for 15 min prior to adhesion: Article Title: Integrin cross-talk modulates stiffness-independent motility of CD4+ T lymphocytes Article Snippet: .. To activate or block integrins, cells were incubated with the following for 15 min prior to adhesion: Control:Article Title: Integrin cross-talk modulates stiffness-independent motility of CD4+ T lymphocytes Article Snippet: .. To activate or block integrins, cells were incubated with the following for 15 min prior to adhesion: Article Title: Integrin cross-talk modulates stiffness-independent motility of CD4+ T lymphocytes Article Snippet: .. To activate or block integrins, cells were incubated with the following for 15 min prior to adhesion: Enzyme-linked Immunosorbent Assay:Article Title: Identification and Validation of a Urinary Biomarker Panel to Accurately Diagnose and Predict Response to Therapy in Lupus Nephritis Article Snippet: .. For the second and third stage of the study, |
